The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions (NCT07278609)
🩺 Plain-English Summary (8th-Grade Level)
The goal of this prospective observational quality improvement study is to determine if a physician tool, MedSafer, combined with educational brochures for patients, can help to reduce the use of 'potentially inappropriate medications' (PIMs) in adults aged 60 and over with rheumatic conditions and polypharmacy (taking 5 or more regular medications). Researchers will follow participants during usual rheumatic disease care. They will compare the rate of PIM deprescribing (stopping medications or reducing the dose) before and after the introduction of the following interventions: * MedSafer reports provided to treating physicians * EMPOWER consumer brochures provided to participants Participants will complete 4 study visits over 18-20 months during which researchers will collect information on medication changes, serious adverse events (emergency visits or hospitalizations), and quality of life.
Who can join: Review the eligibility criteria below.
Location: Montreal General Hospital, McGill University Health Centre — Montreal, Quebec
Age range: 60 Years
🧪 Interventions in This Study
- MedSafer deprescribing opportunity reports, EMPOWER brochures (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Montreal General Hospital, McGill University Health Centre — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 934-1934
Email: arielle.mendel@mcgill.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Rheumatic Diseases
- Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases — Chicago, Illinois
- The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd) — Northport, Alabama
- Personalized Outreach for Equitable Treatment in Rheumatology — Vancouver, British Columbia
- Rheumatology Patient Registry and Biorepository — New Haven, Connecticut
- Studies of the Natural History of Rheumatic Diseases — Bethesda, Maryland
Explore by condition: All Rheumatic Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.